Publication:


abstract

PURPOSE:

Diagnostic imaging is effective for evaluating patients suspected of having hepatocellular carcinoma (HCC). Although the diagnosis can be established with imaging alone, diagnostic biopsy may be useful for patients with tumors measuring 1 to 2 cm. To date, biopsy and imaging use among patients with HCC has not been evaluated in the general community.

PATIENTS AND METHODS:

This cohort study used Surveillance, Epidemiology, and End Results (SEER) -medicare data (2002-2005) evaluating biopsy, imaging modalities (ultrasound, computed tomography [CT] scan, and/or magnetic resonance imaging [MRI]), and HCC risk factors.

RESULTS:

Of 3,696 patients, 1,197 (32.4%) underwent one or more biopsies, with no change in yearly biopsy rate (trend test, P = .64). Patients with tumors > 5 cm were most likely to receive biopsies (35.3%), with increasing rates of biopsy for larger tumors (P = .001). Patients who received biopsies underwent more imaging than those who did not (P < .001) and were more likely to have an HCC risk factor. Tumor size > 5 cm in the setting of a concurrent HCC risk factor increased the odds of biopsy. In 47.8% of patients, the diagnostic sequence was not consistent with contemporary evidence-based guidelines.

CONCLUSIONS:

Despite widespread availability and use of CT scan and MRI, one third of HCC patients undergo biopsy, suggesting a problem with the performance and/or quality of diagnostic imaging or that providers do not believe imaging alone is sufficient to establish the diagnosis. Understanding factors that drive biopsy use may help improve the care of patients with HCC.

Related Articles
[Staging of hepatocellular carcinoma. Comparison of ultrasonography, computerized tomography, magnetic resonance, digital angiography, and computerized tomography with lipiodol].
Radiol Med. 1994
[Staging of hepatocellular carcinoma. Comparison of ultrasonography, computerized tomography, magnetic resonance, digital angiography, and computerized tomography with lipiodol].
Bartolozzi C, Lencioni R, Caramella D, Gibilisco G, Cioni R, Vignali C. Radiol Med. 1994 Oct; 88(4):429-36.
Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Int Surg. 2010
Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Wolfort RM, Papillion PW, Turnage RH, Lillien DL, Ramaswamy MR, Zibari GB. Int Surg. 2010 Jan-Mar; 95(1):67-75.
EUS for detection of the hepatocellular carcinoma: results of a prospective study.
Gastrointest Endosc. 2007
EUS for detection of the hepatocellular carcinoma: results of a prospective study.
Singh P, Erickson RA, Mukhopadhyay P, Gopal S, Kiss A, Khan A, Ulf Westblom T. Gastrointest Endosc. 2007 Aug; 66(2):265-73. Epub 2007 Jun 1.
Review Liver transplantation for hepatocellular carcinoma: role of biopsy.
Liver Transpl. 2007
Review Liver transplantation for hepatocellular carcinoma: role of biopsy.
Durand F, Belghiti J, Paradis V. Liver Transpl. 2007 Nov; 13(11 Suppl 2):S17-23.
Review Imaging diagnosis.
Semin Liver Dis. 2005
Review Imaging diagnosis.
Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. Semin Liver Dis. 2005; 25(2):162-70.
Medicine as it should be: a cultural shift.
J Oncol Pract. 2011
Medicine as it should be: a cultural shift.
Benson AB 3rd. J Oncol Pract. 2011 Sep; 7(5):342-4. Epub 2011 Aug 4.